Cabaletta Bio, Inc.
NASDAQ:CABABiotechnology
+$0.04 today
- Market cap
- $220.03M
- Beta
- 3.23
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.57
Volume 5.46M
Average 3.33M
CABA Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Cabaletta Bio, Inc.NASDAQ: CABA
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses grows, but more slowly than its trailing trend
Q1 FY2026 operating expenses of $44.3M rose 19.3% year over year, behind the +33.6% change in trailing-twelve-month operating expenses. Sequentially, it rose 4.0% from the prior quarter. Over 3 fiscal years it compounded at +47.1% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +19.3% toward the trailing-twelve-month pace of +33.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 172.24M USD
- Year-over-year change
- +37.6%
- 4-year CAGR
- +38.9%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 172.24M | +37.6% |
| FY2024 | 2024-12-31 | 125.14M | +67.6% |
| FY2023 | 2023-12-31 | 74.66M | +37.9% |
| FY2022 | 2022-12-31 | 54.14M | +16.9% |
| FY2021 | 2021-12-31 | 46.31M | — |
Operating Expenses vs competitors
How CABA compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +33.6% is the 3rd highest of 11, against a peer median of -1.1%.
- Over three fiscal years its annual growth of +47.1% compares with a peer median of +13.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $189.56M USD | -47.4% | -10.9% | 611487.1% | |
| LTM Mar 2026 | $179.4M USD | +33.6% | +47.1% | — | |
| LTM Mar 2026 | $162.92M USD | +24.9% | +67.1% | — | |
| LTM Mar 2026 | $149.1M USD | +7.6% | +38.4% | — | |
| LTM Mar 2026 | $117.37M USD | -46.1% | -16.4% | 303.3% | |
| LTM Mar 2026 | $112.97M USD | -32.5% | -15.4% | — | |
| LTM Mar 2026 | $98.8M USD | -9.8% | +5.9% | 4900.7% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $97.24M USD | -16.4% | +21.3% | — |
| LTM Mar 2026 | $77.53M USD | +359.8% | +118.0% | — | |
| FY2025 | A$70.06M AUD | +39.0% | +29.1% | 1388.9% | |
| LTM Mar 2026 | €58.51M EUR | +12.1% | -7.3% | 435.3% | |
| Peer median (excluding CABA) | — | -1.1% | +13.6% | 1388.9% | |
Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.49M | 39.3M | 55.42M | 97.2M | 142.67M |
| Selling, General & Admin | 13.82M | 14.84M | 19.24M | 27.94M | 29.57M |
| Operating Expenses | 46.31M | 54.14M | 74.66M | 125.14M | 172.24M |
| Depreciation & Amortization | 733K | 1.18M | 1.43M | 1.71M | 1.65M |
| EBITDA | (45.56M) | (51.8M) | (66.25M) | (113.41M) | (164.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (46.31M) | (54.14M) | (74.66M) | (125.14M) | (172.24M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 24K | 1.16M | 6.99M | 10.03M | 6.03M |
| Interest Expense | 0 | 0 | 0 | 748K | 2M |
| Other Income / Expenses | 24K | 1.16M | 6.99M | 9.28M | 4.39M |
| Income Before Tax | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.80) | (1.81) | (1.65) | (2.34) | (1.64) |
| EPS (Diluted) | (1.80) | (1.81) | (1.65) | (2.34) | (1.64) |
| Weighted Avg Shares | 25.74M | 29.34M | 40.95M | 49.52M | 102.26M |
| Weighted Avg Shares (Diluted) | 25.74M | 29.34M | 40.95M | 49.47M | 102.26M |
Cabaletta Bio, Inc.
NASDAQ:CABA
Intrinsic Alpha fair value
Locked
Current Price
$1.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.